

Application No. 10/747,671
Response to Restriction Requirement mailed March 28, 2006
Att'y. Dkt. No. C261 1050.1 (51081.0005.4)

CLAIMS


This listing of claims will replace all prior versions, and listings of claims in the application.

1. (Original) A method for inhibiting osteoclast formation in a subject in need thereof, comprising the step of administering a pharmaceutically effective amount of a compound of the general formula ZOC-(CRR)_m-COOH, wherein: m = 2, 3 or 4; Z is OH or NH₂; one R in the compound is from the group consisting of SO₃H, OSO₃H, CH₂-SO₃H, CH₂-OSO₃H, and NHSO₃H, and the remaining Rs are H or NH₂, optionally with an additive, excipient, diluent or carrier.
2. (Original) The method according to claim 1, for inhibiting formation of mononuclear TRAP-positive osteoclasts.
3. (Original) The method according to claim 1, for inhibiting formation of multinuclear TRAP-positive osteoclasts.
4. (Original) The method according to claim 1, wherein the pharmaceutically effective amount is 5 to 10 mg/kg of body weight.
5. (Original) The method according to claim 1, comprising administering the compound for between 5 and 30 days.
6. (Original) The method according to claim 1, comprising administering the compound for at least 30 days.
7. (Original) The method according to claim 1, comprising administering the compound for at least 60 days.


Application No. 10/747,671
Response to Restriction Requirement mailed March 28, 2006
Atty. Dkt. No. C261 1050.1 (S1081.0005.4)

8. (Original) The method according to claim 1, comprising administering the compound for at least 90 days.

9. (Original) The method according to claim 1, wherein the compound has the structure shown below and the formula ZOC-CR₃R₄-CR₁R₂-COOH, wherein one of R₁ to R₄ is selected from the group consisting of SO₃H, OSO₃H, CH₂-SO₃H, ClI₂-OSO₃H, and NHSO₃H, and the remaining are H or NH₂.




10. (Original) The method according to claim 1, wherein the compound has the structure shown below and the formula ZOC-CR₅R₆-CR₃R₄-CR₁R₂-COOH, wherein one of R₁ to R₆ is selected from the group consisting of SO₃H, OSO₃H, CH₂-SO₃H, ClI₂-OSO₃H, and NHSO₃H, and the remaining are H or NH₂.



Application No. 10/747,671
 Response to Restriction Requirement mailed March 28, 2006
 Atty. Dkt. No. C261 1050.1 (51081.0005.4)

11. (Original) The method according to claim 1, wherein the compound has the structure shown below and the formula ZOC-CR₇R₈-CR₅R₆-CR₃R₄-CR₁R₂-COOH, wherein one of R₁ to R₈ is selected from the group consisting of SO₃H, OSO₃H, CH₂-SO₃H, CH₂-OSO₃H, and NHSO₃H, and the remaining are H or NH₂.



STRUCTURE A

12. (Original) The method according to claim 9, wherein the compound is selected from the group consisting of:

- (I) L-Aspartic acid, N-Sulfonic acid,
- (II) L-Aspartic acid, 2β-sulfonic acid,
- (III) L-Aspartic acid, 2β-sulfate,
- (IV) L-aspartic acid, 3α -sulfonic acid,
- (V) L-aspartic acid, 3α -sulfate,
- (VI) L-aspartic acid, 3β-sulfonic acid,
- (VII) L-aspartic acid, 3β-sulfate,
- (VIII) 2α, 3-dicarboxy, propane-1-sulfonic acid,
- (IX) 2α,3-dicarboxy, propane-1-sulfate,
- (X) 1α,2-carboxy ethane sulfonic acid,
- (XI) 1α,2-carboxy ethane sulfate,

Application No. 10/747,671
Response to Restriction Requirement mailed March 28, 2006
Atty. Dkt. No. C261 1050.1 (51081.0005.4)

- (XII) D-aspartic acid, N-sulfonic acid,
- (XIII) 2 β ,3-carboxy,propane-1-sulfonic acid,
- (XIV) 2 β ,3-carboxy,propane-1-sulfate,
- (XV) 1 β ,2-carboxy ethane-1-sulfonic acid,
- (XVI) 1 β ,2-carboxy ethane-1-sulfate,
- (XVII) D-aspartic acid, 2 α -sulfonic acid,
- (XVIII) D-aspartic acid, 2 α -sulfonic acid,
- (XIX) D-Aspartic acid, 3 α -sulfonic acid,
- (XX) D-Aspartic acid, 3 α -sulfate,
- (XXI) D-Aspartic acid, 3 β -sulfonic acid,
- (XXII) D-aspartic acid, 3 β -sulfate,
- (XXIII) L-asparagine,N-sulfonic acid,
- (XXIV) 2 α -carboxy, 3-carboxamido, propane-1-sulfonic acid,
- (XXV) 2 α -carboxy, 3-carboxamido, propane-1-sulfate,
- (XXVI) 1 α -carboxy, 2-carboxamido, ethane sulfonic acid,
- (XXVII) 1 α -carboxy, 2-carboxamido, ethane sulfate,
- (XXVIII) L-asparagine, 2 β -sulfonic acid,
- (XXIX) L-asparagine, 2 β -sulfate,
- (XXX) L-asparagine, 3 α -sulfonic acid,

Application No. 10/747,671

Response to Restriction Requirement mailed March 28, 2006

Atty. Dkt. No. C261 1050.1 (51081.0005.4)

- (XXXI) L-asparagine, 3 α -sulfate,
- (XXXII) L-asparagine, 3 β -sulfonic acid,
- (XXXIII) L-asparagine, 3 β -sulfate,
- (XXXIV) D-asparagine, N-sulfonic acid,
- (XXXV) 2 β -carboxy, 3-carboxamido, propane-1-sulfonic acid,
- (XXXVI) 2 β -carboxy, 3-carboxamido, propane-1-sulfate,
- (XXXVII) 1 β -carboxy, 2-carboxamido, ethane sulfonic acid,
- (XXXVIII) 1 β -carboxy, 2-carboxamido, ethane sulfate,
- (XXXIX) D-asparagine, 2 α -sulfonic acid,
- (XL) D-asparagine, 2 α -sulfate,
- (XLI) D-asparagine, 3 α -sulfonic acid,
- (XLII) D-asparagine, 3 α -sulfate,
- (XLIII) D-asparagine, 3 β -sulfonic acid,
- (XLIV) D-asparagine, 3 β -sulfate.

13. (Original) The method according to claim 10, wherein the compound is selected from the group consisting of:

- (I) L-glutamic acid, N-sulfonic acid,
- (II) 2 α , 4-dicarboxy, butane-1-sulfonic acid,
- (III) 2 α , 4-dicarboxy, butane-1-sulfate,

Application No. 10/747,671

Response to Restriction Requirement mailed March 28, 2006

Atty. Dkt. No. C261 1050.1 (51081.0005.4)

- (IV) 1 α , 3-dicarboxy, propane sulfonic acid,
- (V) 1 α , 3-dicarboxy, propane sulfate,
- (VI) 1 β , 3-dicarboxy, propane sulfate,
- (VII) 1 β , 3-dicarboxy, propane sulfonic acid,
- (VIII) L-glutamic acid, 2 β -sulfonic acid,
- (IX) L-glutamic acid, 2 β -sulfate,
- (X) L-glutamic acid, 3 α -sulfonic acid,
- (XI) L-glutamic acid, 3 α -sulfate,
- (XII) L-glutamic acid, 3 β -sulfonic acid,
- (XIII) L-glutamic acid, 3 β -sulfate,
- (XIV) L-glutamic acid, 4 α -sulfonic acid,
- (XV) L-glutamic acid, 4 α -sulfate,
- (XVI) L-glutamic acid, 4 β -sulfonic acid,
- (XVII) L-glutamic acid, 4 β -sulfate,
- (XVIII) D-glutamic acid, N-sulfonic acid,
- (XIX) 2 β , 4-dicarboxy, butane-1-sulfonic acid,
- (XX) 2 β , 4-dicarboxy, butane-1-sulfate,
- (XXI) D-glutamic acid, 2 α -sulfonic acid,
- (XXII) D-glutamic acid, 2 α -sulfate,

Application No. 10/747,671

Response to Restriction Requirement mailed March 28, 2006

Atty. Dkt. No. C261 1050.1 (51081.0005.4)

- (XXIII) D-glutamic acid, 3 α -sulfonic acid,
- (XXIV) D-glutamic acid, 3 α -sulfate,
- (XXV) D-glutamic acid, 3 β -sulfonic acid,
- (XXVI) D-glutamic acid, 3 β -sulfate,
- (XXVII) D-glutamic acid, 4 α -sulfonic acid,
- (XXVIII) D-glutamic acid, 4 α -sulfate,
- (XXIX) D-glutamic acid, 4 β -sulfonic acid,
- (XXX) D-glutamic acid, 4 β -sulfate,
- (XXXI) L-glutamine, N-sulfonic acid,
- (XXXII) L-glutamine, 2 β -sulfonic acid,
- (XXXIII) L-glutamine, 2 β -sulfate,
- (XXXIV) L-glutamine, 3 α -sulfonic acid,
- (XXXV) L-glutamine, 3 α -sulfate,
- (XXXVI) L-glutamine, 3 β -sulfonic acid,
- (XXXVII) L-glutamine, 3 β -sulfate,
- (XXXVIII) L-glutamine, 4 α -sulfonic acid,
- (XXXIX) L-glutamine, 4 α -sulfate,
- (XL) L-glutamine, 4 β -sulfonic acid,
- (XLI) L-glutamine, 4 β -sulfate,

Application No. 10/747,671

Response to Restriction Requirement mailed March 28, 2006

Atty. Dkt. No. C261 1050.1 (51081.0005.4)

- (XLII) 2 α -carboxy, 4-carboxamido, butane-1-sulfonic acid,
- (XLIII) 2 α -carboxy, 4-carboxamido, butane-1-sulfate,
- (XLIV) 1 α -carboxy, 3-carboxamido, propane-1-sulfonic acid,
- (XLV) 1 α -carboxy, 3-carboxamido, propane-1-sulfate,
- (XLVI) 1 β -carboxy, 3-carboxamido, propane-1-sulfate,
- (XLVII) 1 β -carboxy, 3-carboxamido, propane-1-sulfonic acid,
- (XLVIII) D-glutamine, N-sulfonic acid,
- (XLIX) 2 β -carboxy, 4-carboxamido, butane-1-sulfonic acid,
- (L) 2 β -carboxy, 4-carboxamido, butane-1-sulfate,
- (LI) D-glutamine, 2 α -sulfonic acid,
- (LII) D-glutamine, 2 α -sulfate,
- (LIII) D-glutamine, 3 α -sulfonic acid,
- (LIV) D-glutamine, 3 α -sulfate,
- (LV) D-glutamine, 3 β -sulfonic acid,
- (LVI) D-glutamine, 3 β -sulfate,
- (LVII) D-glutamine, 4 α -sulfonic acid,
- (LVIII) D-glutamine, 4 α -sulfate,
- (LIX) D-glutamine, 4 β -sulfonic acid,
- (LX) D-glutamine, 4 β -sulfate.

Application No. 10/747,671

Response to Restriction Requirement mailed March 28, 2006

Atty. Dkt. No. C261 1050.1 (51081.0005.4)

14. (Original) The method according to claim 11, wherein the compound is selected from the group consisting of:

- (I) L-homoglutamic acid, N-sulfonic acid,
- (II) Pentane-2 α , 5-dicarboxy-1-sulfonic acid,
- (III) Pentane-2 α , 5-dicarboxy-1-sulfate,
- (IV) Butane-1 α , 4-dicarboxy-1-sulfonic acid,
- (V) Butane-1 α , 4-dicarboxy-1-sulfate,
- (VI) L-homoglutamic acid, 2 β -sulfonic acid,
- (VII) L-homoglutamic acid, 2 β -sulfate,
- (VIII) L-homoglutamic acid, 3 α -sulfonic acid,
- (IX) L-homoglutamic acid, 3 α -sulfate,
- (X) L-homoglutamic acid, 3 β -sulfonic acid,
- (XI) L-homoglutamic acid, 3 β -sulfate,
- (XII) L-homoglutamic acid, 4 α -sulfonic acid,
- (XIII) L-homoglutamic acid, 4 α -sulfate,
- (XIV) L-homoglutamic acid, 4 β -sulfonic acid,
- (XV) L-homoglutamic acid, 4 β -sulfate,
- (XVI) L-homoglutamic acid, 5 α -sulfonic acid,
- (XVII) L-homoglutamic acid, 5 α -sulfate,
- (XVIII) L-homoglutamic acid, 5 β -sulfonic acid,

Application No. 10/747,671

Response to Restriction Requirement mailed March 28, 2006

Atty. Dkt. No. C261 1050.1 (51081.0005.4)

- (XIX) L-homoglutamic acid, 5 β -sulfate,
- (XX) D-homoglutamic acid, N-sulfonic acid,
- (XXI) Pentane-2 β , 5-dicarboxy-1-sulfonic acid,
- (XXII) Pentane-2 β , 5-dicarboxy-1-sulfate,
- (XXIII) Butane-1 β , 4-dicarboxy-1-sulfonic acid,
- (XXIV) Butane-1 β , 4-dicarboxy-1-sulfate,
- (XXV) D-homoglutamic acid, 2 α -sulfonic acid,
- (XXVI) D-homoglutamic acid, 2 α -sulfate,
- (XXVII) D-homoglutamic acid, 3 α -sulfonic acid,
- (XXVIII) D-homoglutamic acid, 3 α -sulfate,
- (XXIX) D-homoglutamic acid, 3 β -sulfonic acid,
- (XXX) D-homoglutamic acid, 3 β -sulfate,
- (XXXI) D-homoglutamic acid, 4 α -sulfonic acid,
- (XXXII) D-homoglutamic acid, 4 α -sulfate,
- (XXXIII) D-homoglutamic acid, 4 β -sulfonic acid,
- (XXXIV) D-homoglutamic acid, 4 β -sulfate,
- (XXXV) D-homoglutamic acid, 5 α -sulfonic acid,
- (XXXVI) D-homoglutamic acid, 5 α -sulfate,
- (XXXVII) D-homoglutamic acid, 5 β -sulfonic acid,

Application No. 10/747,671

Response to Restriction Requirement mailed March 28, 2006

Atty. Dkt. No. C261 1050.1 (51081.0005.4)

- (XXXVII) D-homoglutamic acid, 5 β -sulfate,
- (XXXIX) L-homoglutamine, N-sulfonic acid,
- (XL) Pentane-2 α -carboxy, 5-carboxamido-1-sulfonic acid,
- (XLI) Pentane-2 α -carboxy, 5-carboxamido-1-sulfate,
- (XLII) Butane-1 α -carboxy, 4-carboxamido-1-sulfonic acid,
- (XLIII) Butane-1 α -carboxy, 4-carboxamido-1-sulfate,
- (XLIV) L-homoglutamine, 2 β -sulfonic acid,
- (XLV) L-homoglutamine, 2 β -sulfate,
- (XLVI) L-homoglutamine, 3 α -sulfonic acid,
- (XLVII) L-homoglutamine, 3 α -sulfate,
- (XLVIII) L-homoglutamine, 3 β -sulfonic acid,
- (XLIX) L-homoglutamine, 3 β -sulfate,
- (L) L-homoglutamine, 4 α -sulfonic acid,
- (LI) L-homoglutamine, 4 α -sulfate,
- (LII) L-homoglutamine, 4 β -sulfonic acid,
- (LIII) L-homoglutamine, 4 β -sulfate,
- (LIV) L-homoglutamine, 5 α -sulfonic acid,
- (LV) L-homoglutamine, 5 α -sulfate,
- (LVI) L-homoglutamine, 5 β -sulfonic acid,

Application No. 10/747,671

Response to Restriction Requirement mailed March 28, 2006

Atty. Dkt. No. C261 1050.1 (51081.0005.4)

- (LVI) L-homoglutamine, 5 β -sulfate,
- (LVII) D-homoglutamine, N-sulfonic acid,
- (LVIII) Pentane-2 β -carboxy, 5-carboxamido-1-sulfonic acid,
- (LIX) Pentane-2 β -carboxy, 5-carboxamido-1-sulfate,
- (LX) Butane-1 β -carboxy, 4-carboxamido-1-sulfonic acid,
- (LXI) Butane-1 β -carboxy, 4-carboxamido-1-sulfate,
- (LXII) D-homoglutamine, 2 α -sulfonic acid,
- (LXIII) D-homoglutamine, 2 α -sulfate,
- (LXIV) D-homoglutamine, 3 α -sulfonic acid,
- (LXV) D-homoglutamine, 3 α -sulfate,
- (LXVI) D-homoglutamine, 3 β -sulfonic acid,
- (LXVII) D-homoglutamine, 3 β -sulfate,
- (LXVIII) D-homoglutamine, 4 α -sulfonic acid,
- (LXIX) D-homoglutamine, 4 α -sulfate,
- (LXX) D-homoglutamine, 4 β -sulfonic acid,
- (LXXI) D-homoglutamine, 4 β -sulfate,
- (LXXII) D-homoglutamine, 5 α -sulfonic acid,
- (LXXIII) D-homoglutamine, 5 α -sulfate,
- (LXXIV) D-homoglutamine, 5 β -sulfonic acid,
- (LXXV) D-homoglutamine, 5 β -sulfate,

Application No. 10/747,671

Response to Restriction Requirement mailed March 28, 2006

Atty. Dkt. No. C261 1050.1 (51081.0005.4)

(LXXVI) D-homoglutamine, 5 β -sulfate.

Claims 15-28. (Cancelled)